$ENTB Zander's Chairman & CEO David Koos noted, "With the addition of these new management team members, Zander is poised to advance its business model rapidly. We have both proprietary intellectual property and licensed intellectual property (from Regen BioPharma Inc.), which are aimed at addressing maladies suffered by our pets through the development of small molecule therapies. The veterinary market is something I'm extremely passionate about, as I have two basset hounds and lost my first basset hound to cancer. I'm excited that Zander can provide therapies that prevent the suffering of our pets."

http://finance.yahoo.com/news/entest-biomedic...NlYwNzYw--